Cambrian BioPharma Inc - 31 Jul 2023 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role
Other*, 10%+ Owner
Signature
Cambrian BioPharma Inc, by: /s/ James Peyer
Issuer symbol
SNSE
Transactions as of
31 Jul 2023
Net transactions value
-$2,000,001
Form type
4
Filing time
02 Aug 2023, 17:09:45 UTC
Previous filing
12 Jul 2023
Next filing
13 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNSE Common Stock Disposed to Issuer $2,000,001 -1,587,302 -30% $1.26 3,653,120 31 Jul 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares purchased by the Issuer pursuant to a Purchase Agreement, dated July 31, 2023, by and among the Issuer, the Reporting Person and James Peyer. This transaction, which was approved by the Board of Directors of the Issuer, is exempt pursuant to Rule 16b-3(e) of the Securities Exchange Act of 1934, as amended.
F2 These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

Remarks:

The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. James Peyer is also a director of the Issuer, and Cambrian may be deemed to be a director of the Issuer by deputization of James Peyer.